article Open AccessTop 1% cited

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine · 2015 · Vol. 373(22) · pp. 2117–2128

Bernard Zinman✉(Lunenfeld-Tanenbaum Research Institute)Christoph Wanner(University of Würzburg)John M. Lachin(George Washington University)David Fitchett(University of Toronto)Erich Bluhmki(Boehringer Ingelheim (Germany))Stefan Hantel(Boehringer Ingelheim (Germany))Michaela Mattheus(Boehringer Ingelheim (Taiwan))Theresa Devins(Boehringer Ingelheim (United States))Odd Erik Johansen(Boehringer Ingelheim (Norway))Hans J. Woerle(Boehringer Ingelheim (Taiwan))Uli C. Broedl(Boehringer Ingelheim (Taiwan))Silvio E. Inzucchi(Yale University)

View via DOI Full-text PDF

Abstract

Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes Management and ResearchEmpagliflozinMedicineHazard ratioMyocardial infarctionInternal medicinePlaceboConfidence intervalRelative riskDiabetes mellitusStroke (engine)

MeSH terms

AgedBenzhydryl CompoundsCardiovascular DiseasesCause of DeathDiabetes Mellitus, Type 2FemaleGlucosidesHospitalizationHumansHypoglycemic AgentsMaleMiddle AgedRisk FactorsKaplan-Meier EstimateIntention to Treat Analysis

Citations

11,756

FWCI

622.47

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease